FDA gives TAR-200 Priority Review for invasive bladder cancer

ODAC nixes GSK’s Blenrep myeloma regimens, citing ocular toxicity, dosing, applicability to U.S. population

The FDA Oncologic Drugs Advisory Committee July 17 recommended against approval of a Blenrep-based regimen for the treatment of relapsed or refractory multiple myeloma, citing unacceptable rates of ocular toxicity and overall poor tolerability of the drug.

July 18, 2025

Vol.51 No.28

By Jacquelyn Cobb and Sara Willa Ernst

Imaging’s ride to the bottom in clinical trials—and why it matters now

In cancer care, imaging has become a marvel of modern medicine. Advances in scanner technology, reconstruction algorithms, contrast agents, and diagnostic protocols have radically improved our ability to detect, track, and understand disease. Clinically, imaging is fast, accurate, and central to decision-making.

NIH says it’s moving away from animal-based models

NIH has announced that it will no longer be issuing Notices of Funding Opportunities exclusively supporting animal models.

July 18, 2025

Vol.51 No.28

By Claire Marie Porter

In the Archives

Rick and Mary Pazdur on facing “the other side of the stethoscope”
A few months before Mary died of ovarian cancer, the couple shared how this experience shaped their perspectives on oncology

The Pazdurs in their garden with their dog, Cleo. The dog’s full name is Cleopatra, Queen of Denial.In 1999, Rick Pazdur went in for a “perfunctory” final interview at FDA. Thinking it would only take a few minutes, his wife, Mary, decided to wait and have a quick cup of coffee at a nearby restaurant—Hooters.

In the name of “radical transparency,” FDA touts publication of 200 complete response letters

In a move advertised as being in line with FDA’s goal of “radical transparency,” the agency July 10 announced the publication of more than 200 complete response letters.

FDA grants accelerated approval to Zegfrovy for NSCLC with EGFR exon20ins

FDA has approved Zegfrovy (sunvozertinib) for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.

July 03, 2025

Vol.51 No.26

FDA gives TAR-200 Priority Review for invasive bladder cancer

YOU MAY BE INTERESTED IN

ODAC nixes GSK’s Blenrep myeloma regimens, citing ocular toxicity, dosing, applicability to U.S. population

Imaging’s ride to the bottom in clinical trials—and why it matters now

NIH says it’s moving away from animal-based models

Rick and Mary Pazdur on facing “the other side of the stethoscope”
A few months before Mary died of ovarian cancer, the couple shared how this experience shaped their perspectives on oncology

In the name of “radical transparency,” FDA touts publication of 200 complete response letters

FDA grants accelerated approval to Zegfrovy for NSCLC with EGFR exon20ins

Renew today!

Subscriber content

Never miss an issue!

Login

FDA gives TAR-200 Priority Review for invasive bladder cancer

YOU MAY BE INTERESTED IN

ODAC nixes GSK’s Blenrep myeloma regimens, citing ocular toxicity, dosing, applicability to U.S. population

Imaging’s ride to the bottom in clinical trials—and why it matters now

NIH says it’s moving away from animal-based models

Rick and Mary Pazdur on facing “the other side of the stethoscope”A few months before Mary died of ovarian cancer, the couple shared how this experience shaped their perspectives on oncology

In the name of “radical transparency,” FDA touts publication of 200 complete response letters

FDA grants accelerated approval to Zegfrovy for NSCLC with EGFR exon20ins

Never miss an issue!

Login

Rick and Mary Pazdur on facing “the other side of the stethoscope”
A few months before Mary died of ovarian cancer, the couple shared how this experience shaped their perspectives on oncology